AmpliPhi announces pre-clinical data

Efficacy of a bacteriophage cocktail is comparable to Vancomycin in S. aureus lung infection model

21-Sep-2015 - AmpliPhi Biosciences Corporation announced experimental results highlighting that its prototype bacteriophage cocktail demonstrated comparable efficacy to vancomycin in reduction of Staphylococcus aureus (S. aureus) in a murine lung infection model. “We are encouraged by these positive results, ...

AmpliPhi’s Bacteriophage Manufacturing Facility Receives cGMP Certification

First cGMP-certified manufacturing facility commissioned to manufacture bacteriophage products for human use

08-Jun-2015 - AmpliPhi BioSciences Corporation announced that its production facility in Ljubljana, Slovenia, was cleared by JAZMP, the Agency of the Republic of Slovenia for Medicinal Products and Medical Devices, to manufacture bacteriophages under current Good Manufacturing Practices (cGMP) standards. ...

AmpliPhi Biosciences Announces New CEO

05-May-2015 - AmpliPhi BioSciences Corporation announced that Scott Salka has been appointed as the new CEO. Mr. Salka will replace Interim CEO and Chairman of AmpliPhi, Jeremy Curnock Cook, effective May 18. Mr. Curnock Cook will remain in his role as Chairman.Since 2010, Mr. Salka has served as CEO of ...

AmpliPhi Granted European Patent for Bacteriophage Therapy to Fight Biofilm-related Bacterial Infections

07-Apr-2015 - AmpliPhi BioSciences Corporation announced that the European Patent Office (EPO) has granted European patent no. EP 2570130, “Bacteriophage-containing Therapeutic Agents”. Three related patents have been issued in the United States (U.S. Patent Nos. 7,807,149, 8,105,579, and 8,388,946), the ...

AmpliPhi and Special Phage Services complete merger

20-Nov-2012 - AmpliPhi Biosciences Corporation and Special Phage Services (SPS) are formally combined following the completion of the share exchange transaction. Now trading as Ampliphi, the enlarged company combines complementary technologies and expertise in bacteriophage-based therapies to create an ...

AmpliPhi to combine with Special Phage Services to create anti-infective company focused on bacteriophage-based therapies

13-Sep-2012 - AmpliPhi Biosciences Corporation announced that it has offered to acquire Special Phage Services (“SPS”). The combination of the two companies would result in the creation of a leading anti-infective company focused on developing phage-based therapies to combat the growing threat of ...

AmpliPhi Biosciences announces first closing of $2.7m

21-Nov-2011 - AmpliPhi Biosciences Corporation has announced that is has closed on an initial amount of $2.7M in equity investment and convertible loan notes to support the further progress of the Company. In total, the Company is seeking up to $5m in this round.This initial round was led by prominent ...

AmpliPhi Biosciences appoints Philip J. Young as President and CEO

14-Nov-2011 - AmpliPhi Biosciences Corporation has announced the appointment of Philip J. Young as President and Chief Executive Officer (CEO).Mr. Young, who is based in the US, is a long time executive in the biopharmaceuticals industry. He is the former president and CEO of Osteologix Inc., a global ...